regeneron bispecific antibody targeting bcma update | joshua richter, md | ash 2021
Published 2 years ago • 312 plays • Length 1:28Download video MP4
Download video MP3
Similar videos
-
3:11
bispecific antibodies | joshua richter, md | ash 2022
-
2:18
t cell re-direction therapy | joshua richter, md | eha 2022
-
1:53
istopmm study and early mgus and smm screening | joshua richter, md | ash 2021
-
7:18
response rate on phase 1/2 trial regn5458 (bcmaxcd3 bispecific antibody) for rrmm patients
-
2:25
cevostamab in rrmm patients: camma 2 study results | joshua richter, md | eha 2024
-
1:25
safety and efficacy of linvoseltamab for patients with r/r multiple myeloma
-
57:20
know your myeloma immunotherapy: bispecific antibodies with dr. cesar rodriguez
-
5:20
what are bispecifics in multiple myeloma? (for patients and caregivers) | dr. joshua richter
-
21:02
emerging bispecifics myeloma patients should know about | dr. joshua richter | the patient story
-
7:09
what is regeneron covid-19 monoclonal antibody treatment?
-
51:21
t. libermann - next generation proteomics driving precision medicine
-
2:57
quad therapy in newly diagnosed myeloma using mrd testing | matt pianko, md | ash 2021
-
2:06
safety & efficacy of cevostamab in patients with heavily pre-treated r/r multiple myeloma
-
10:16
selinexor in multiple myeloma — dr. joshua richter | mcrt webcast july 11
-
14:02
regn5459 | therapies on the horizon
-
1:47
insights into the efficacy of linvoseltamab in the treatment of r/r multiple myeloma
-
2:03
ash 2018: selexinor results in tow trials: storm and stomp
-
14:31
teclistamab - guest lecture
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
2:12
safety and efficacy of regn5458 in patients with relapsed/refractory (r/r) multiple myeloma
-
12:26
treating ultra high risk myeloma patients in a unique uk study | martin kaiser, md | ash 2021
-
1:38
the efficacy of cevostamab in r/r multiple myeloma and the importance of bispecific antibodies